Stroke is the third leading cause of death in the United States and the number one cause of adult long-term disability. Disability in stroke survivors includes hemiparesis, aphasia, inability to walk without assistance, dependence on others for activities of daily living, depression, and institutionalization. Immediate recognition of acute ischemic stroke (AIS) signs and symptoms is required because many treatment options are time sensitive. Hospital transport via activation of 911 and emergency medical services (EMSs) removes delays to urgent diagnosis and intervention. Intravenous (IV) recombinant tissue plasminogen (rt-PA) is a time-sensitive reperfusion strategy. The American Heart Association (AHA) and American Stroke Association (ASA) recently revised recommendations that the time window for IV rt-PA be expanded from 3 hours to 4.5 hours after symptom onset in patients with mild to moderate stroke. Supportive therapies include crystalloid IV solutions, adequate oxygenation, and normothermia. Best rest is desired along with oxygen supplementation. Avoidance of fever is paramount since fever can contribute to negative outcomes. It is the purpose of this article to review risk factors, stroke symptoms, epidemiology, and current drug therapy of AIS. Standards of care will be reviewed.
AdamsHP,JrBendixenBHKappelleLJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.
2.
BriggsDEFelbergRAMalkoffMD. Should mild or moderate stroke patients be admitted to an intensive care unit?Stroke. 2001;32(4):871–876.
Lloyd-JonesDAdamsRCarnethonM. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–486.
7.
Lloyd-JonesDAdamsRCarnethonM. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–e181.
GoldsteinLBAdamsRAlbertsMJ. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37(6):1583–1633.
11.
. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
12.
PutaalaJMetsoAJMetsoTM. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. 2009;40(4):1195–1203.
13.
WolfPAAbbottRDKannelWB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
AdamsHPJrdel ZoppoGAlbertsMJ. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655–1711.
19.
KurthT. Associations between migraine and cardiovascular disease. Expert Rev Neurother. 2007;7(9):1097–1104.
20.
Wassertheil-SmollerSHendrixSLLimacherM. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–2684.
21.
BanderaEBotteriMMinelliC. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke. 2006;37(5):1334–1339.
22.
RoseJCMayerSA. Optimizing blood pressure in neurological emergencies. Neurocrit Care. 2004;1(3):287–299.
SwitzerJAHessDC. Development of regional programs to speed treatment of stroke. Curr Neurol Neurosci Rep. 2008;8(1):35–42.
27.
SaposnikGKapralMKCouttsSB. Do all age groups benefit from organized inpatient stroke care?Stroke. 2009;40(10):3321–3327.
28.
FoerchCMontanerJFurieKL. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology. 2009;73(5):393–399.
29.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–1587.
30.
HackeWKasteMBluhmkiE. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
31.
SaverJLGornbeinJGrottaJ. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke. 2009;40(7):2433–2437.
32.
Del ZoppoGJSaverJLJauchEC. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945–2948.
33.
HackeWDonnanGFieschiC. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.
34.
SmithWSSungGSaverJ. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39(4):1205–1212.
35.
BoseAHenkesHAlfkeK. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008;29(7):1409–1413.
36.
Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40(8):2761–2768.
37.
Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39(4)1205–1212.
38.
Investigators. TIIT. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38(7):2127–2135.
39.
PancioliAMBroderickJBrottT. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39(12):3268–3276.
AlbersGWAmarencoPEastonJD. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):630S–669S.
42.
MeyerDMAlbrightKCAllisonTA. LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis. 2008;17(1):26–29.
43.
KennedyJHillMDRyckborstKJ. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6(11):961–969.
44.
DenglerRDienerHCSchwartzA. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(2):159–166.
45.
SteadLGGilmoreRMDeckerWW. Initial emergency department blood pressure as predictor of survival after acute ischemic stroke. Neurology. 2005;65(8):1179–1183.
46.
SteadLGGilmoreRMVedulaKC. Impact of acute blood pressure variability on ischemic stroke outcome. Neurology. 2006;66(12):1878–1881.
47.
BroderickJConnollySFeldmannE. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001–2023.
48.
ShermanDGAlbersGWBladinC. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007;369(9570):1347–1355.
49.
CapesSEHuntDMalmbergK. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32(10):2426–2432.
50.
QuinnTJLeesKR. Hyperglycaemia in acute stroke—to treat or not to treat. Cerebrovasc Dis. 2009;27(suppl 1):148–155.
51.
JohnstonKCHallCEKisselaBM. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke. 2009;40(12):3804–3809.
52.
BrunoAKentTACoullBM. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke. 2008;39(2):384–389.
53.
GrayCSHildrethAJAlbertiGK. Poststroke hyperglycemia: natural history and immediate management. Stroke. 2004;35(1):122–126.
54.
NeuSTART II Neuroprotection with Statin Therapy for Acute Recovery Trial (Neu START): a phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke. http://www.strokecenter.org/trials/TrialDetail.aspx?tid=971. Accessed November 13, 2009.
55.
AmarencoPBogousslavskyJCallahanA.3rd. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
56.
BlancoMNombelaFCastellanosM. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904–910.
57.
SaccoRLAdamsRAlbersG. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577–617.
58.
ClarkWM. Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother. 2009;10(5):839–846.
